Baidu
map

JCI:我科学家人类肝癌干细胞自我更新机制

2015-09-07 佚名 生物谷

近日,来自中科院生物物理所的范祖森研究小组在国际学术期刊JCI上发表了一项最新研究进展,他们在肝癌干细胞中发现转录因子ZIC2表达水平较高,并对其维持肝癌干细胞自我更新的作用机制进行了研究。肝细胞癌(HCC)是全世界最常见的癌症类型之一,复发率高和肿瘤异质性是这种癌症的两个主要特征。近年来一些研究提出癌症干细胞模型,他们发现一小群具有自我更新能力的癌症干细胞能够分化形成新的肿瘤细胞,并认为癌症干细

近日,来自中科院生物物理所的范祖森研究小组在国际学术期刊JCI上发表了一项最新研究进展,他们在肝癌干细胞中发现转录因子ZIC2表达水平较高,并对其维持肝癌干细胞自我更新的作用机制进行了研究。

肝细胞癌(HCC)是全世界最常见的癌症类型之一,复发率高和肿瘤异质性是这种癌症的两个主要特征。近年来一些研究提出癌症干细胞模型,他们发现一小群具有自我更新能力的癌症干细胞能够分化形成新的肿瘤细胞,并认为癌症干细胞是维持肿瘤生长以及对传统治疗方法产生抵抗的重要原因。尽管目前已经能够通过一些表面标记对肝癌干细胞进行富集,但是人们对于肝癌干细胞的了解仍然不足。

在这项研究中,研究人员对肝癌干细胞和普通HCC细胞的转录组表达谱进行了分析,结果发现转录因子ZIC2在肝癌干细胞中表达水平很高。他们发现ZIC2对于肝癌干细胞的自我更新具有非常重要的作用,删除ZIC2能够显著减弱肝癌干细胞的球体形成(sphere formation)能力,并可以抑制移植瘤在小鼠体内的生长。

随后,研究人员对ZIC2的作用机制进行了探究,他们发现ZIC2作用于转录因子OCT4的上游,ZIC2能够将核重塑因子复合体NURF招募到OCT4的启动子区域,进而起始OCT4的转录激活。研究人员在HCC病人中发现NURF复合体的表达水平与HCC的临床进展和预后呈现一致性,并且ZIC2和OCT4的表达水平与HCC病人所处的临床病理学阶段成正相关性。

总的来说,这项研究表明转录因子ZIC2,OCT4以及核重塑因子复合物NURF可以作为HCC疾病诊断标记并可预测HCC病人的预后情况,同时这三个因子还可以作为根除肝癌干细胞的潜在靶向目标在HCC的治疗中发挥重要作用。

原文出处:

Pingping Zhu1, Yanying Wang1,et al.ZIC2-dependent OCT4 activation drives self-renewal of human liver cancer stem cells.JCI.2015


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1659300, encodeId=f43c165930004, content=<a href='/topic/show?id=7287861e2ed' target=_blank style='color:#2F92EE;'>#自我更新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86172, encryptionId=7287861e2ed, topicName=自我更新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=764624964499, createdName=xsm926, createdTime=Tue Apr 19 20:03:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805371, encodeId=151218053e182, content=<a href='/topic/show?id=9d42e801133' target=_blank style='color:#2F92EE;'>#细胞自我更新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78011, encryptionId=9d42e801133, topicName=细胞自我更新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Mon Oct 26 23:03:00 CST 2015, time=2015-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982019, encodeId=af6e198201910, content=<a href='/topic/show?id=12c010266f0' target=_blank style='color:#2F92EE;'>#JCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10266, encryptionId=12c010266f0, topicName=JCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Fri Jan 22 15:03:00 CST 2016, time=2016-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36627, encodeId=c4323662e32, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 10:19:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36626, encodeId=353a366264a, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 10:18:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544970, encodeId=a50015449e0a8, content=<a href='/topic/show?id=7a0fe1289c2' target=_blank style='color:#2F92EE;'>#癌干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71289, encryptionId=7a0fe1289c2, topicName=癌干细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=340013676140, createdName=1249898am19暂无昵称, createdTime=Wed Sep 09 00:03:00 CST 2015, time=2015-09-09, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1659300, encodeId=f43c165930004, content=<a href='/topic/show?id=7287861e2ed' target=_blank style='color:#2F92EE;'>#自我更新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86172, encryptionId=7287861e2ed, topicName=自我更新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=764624964499, createdName=xsm926, createdTime=Tue Apr 19 20:03:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805371, encodeId=151218053e182, content=<a href='/topic/show?id=9d42e801133' target=_blank style='color:#2F92EE;'>#细胞自我更新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78011, encryptionId=9d42e801133, topicName=细胞自我更新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Mon Oct 26 23:03:00 CST 2015, time=2015-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982019, encodeId=af6e198201910, content=<a href='/topic/show?id=12c010266f0' target=_blank style='color:#2F92EE;'>#JCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10266, encryptionId=12c010266f0, topicName=JCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Fri Jan 22 15:03:00 CST 2016, time=2016-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36627, encodeId=c4323662e32, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 10:19:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36626, encodeId=353a366264a, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 10:18:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544970, encodeId=a50015449e0a8, content=<a href='/topic/show?id=7a0fe1289c2' target=_blank style='color:#2F92EE;'>#癌干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71289, encryptionId=7a0fe1289c2, topicName=癌干细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=340013676140, createdName=1249898am19暂无昵称, createdTime=Wed Sep 09 00:03:00 CST 2015, time=2015-09-09, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1659300, encodeId=f43c165930004, content=<a href='/topic/show?id=7287861e2ed' target=_blank style='color:#2F92EE;'>#自我更新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86172, encryptionId=7287861e2ed, topicName=自我更新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=764624964499, createdName=xsm926, createdTime=Tue Apr 19 20:03:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805371, encodeId=151218053e182, content=<a href='/topic/show?id=9d42e801133' target=_blank style='color:#2F92EE;'>#细胞自我更新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78011, encryptionId=9d42e801133, topicName=细胞自我更新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Mon Oct 26 23:03:00 CST 2015, time=2015-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982019, encodeId=af6e198201910, content=<a href='/topic/show?id=12c010266f0' target=_blank style='color:#2F92EE;'>#JCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10266, encryptionId=12c010266f0, topicName=JCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Fri Jan 22 15:03:00 CST 2016, time=2016-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36627, encodeId=c4323662e32, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 10:19:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36626, encodeId=353a366264a, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 10:18:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544970, encodeId=a50015449e0a8, content=<a href='/topic/show?id=7a0fe1289c2' target=_blank style='color:#2F92EE;'>#癌干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71289, encryptionId=7a0fe1289c2, topicName=癌干细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=340013676140, createdName=1249898am19暂无昵称, createdTime=Wed Sep 09 00:03:00 CST 2015, time=2015-09-09, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1659300, encodeId=f43c165930004, content=<a href='/topic/show?id=7287861e2ed' target=_blank style='color:#2F92EE;'>#自我更新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86172, encryptionId=7287861e2ed, topicName=自我更新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=764624964499, createdName=xsm926, createdTime=Tue Apr 19 20:03:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805371, encodeId=151218053e182, content=<a href='/topic/show?id=9d42e801133' target=_blank style='color:#2F92EE;'>#细胞自我更新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78011, encryptionId=9d42e801133, topicName=细胞自我更新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Mon Oct 26 23:03:00 CST 2015, time=2015-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982019, encodeId=af6e198201910, content=<a href='/topic/show?id=12c010266f0' target=_blank style='color:#2F92EE;'>#JCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10266, encryptionId=12c010266f0, topicName=JCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Fri Jan 22 15:03:00 CST 2016, time=2016-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36627, encodeId=c4323662e32, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 10:19:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36626, encodeId=353a366264a, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 10:18:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544970, encodeId=a50015449e0a8, content=<a href='/topic/show?id=7a0fe1289c2' target=_blank style='color:#2F92EE;'>#癌干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71289, encryptionId=7a0fe1289c2, topicName=癌干细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=340013676140, createdName=1249898am19暂无昵称, createdTime=Wed Sep 09 00:03:00 CST 2015, time=2015-09-09, status=1, ipAttribution=)]
    2015-09-10 he408015781

    期待进一步的研究

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1659300, encodeId=f43c165930004, content=<a href='/topic/show?id=7287861e2ed' target=_blank style='color:#2F92EE;'>#自我更新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86172, encryptionId=7287861e2ed, topicName=自我更新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=764624964499, createdName=xsm926, createdTime=Tue Apr 19 20:03:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805371, encodeId=151218053e182, content=<a href='/topic/show?id=9d42e801133' target=_blank style='color:#2F92EE;'>#细胞自我更新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78011, encryptionId=9d42e801133, topicName=细胞自我更新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Mon Oct 26 23:03:00 CST 2015, time=2015-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982019, encodeId=af6e198201910, content=<a href='/topic/show?id=12c010266f0' target=_blank style='color:#2F92EE;'>#JCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10266, encryptionId=12c010266f0, topicName=JCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Fri Jan 22 15:03:00 CST 2016, time=2016-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36627, encodeId=c4323662e32, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 10:19:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36626, encodeId=353a366264a, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 10:18:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544970, encodeId=a50015449e0a8, content=<a href='/topic/show?id=7a0fe1289c2' target=_blank style='color:#2F92EE;'>#癌干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71289, encryptionId=7a0fe1289c2, topicName=癌干细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=340013676140, createdName=1249898am19暂无昵称, createdTime=Wed Sep 09 00:03:00 CST 2015, time=2015-09-09, status=1, ipAttribution=)]
    2015-09-10 he408015781

    期待进一步的研究

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1659300, encodeId=f43c165930004, content=<a href='/topic/show?id=7287861e2ed' target=_blank style='color:#2F92EE;'>#自我更新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86172, encryptionId=7287861e2ed, topicName=自我更新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=764624964499, createdName=xsm926, createdTime=Tue Apr 19 20:03:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805371, encodeId=151218053e182, content=<a href='/topic/show?id=9d42e801133' target=_blank style='color:#2F92EE;'>#细胞自我更新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78011, encryptionId=9d42e801133, topicName=细胞自我更新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Mon Oct 26 23:03:00 CST 2015, time=2015-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982019, encodeId=af6e198201910, content=<a href='/topic/show?id=12c010266f0' target=_blank style='color:#2F92EE;'>#JCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10266, encryptionId=12c010266f0, topicName=JCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Fri Jan 22 15:03:00 CST 2016, time=2016-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36627, encodeId=c4323662e32, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 10:19:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36626, encodeId=353a366264a, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 10:18:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544970, encodeId=a50015449e0a8, content=<a href='/topic/show?id=7a0fe1289c2' target=_blank style='color:#2F92EE;'>#癌干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71289, encryptionId=7a0fe1289c2, topicName=癌干细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=340013676140, createdName=1249898am19暂无昵称, createdTime=Wed Sep 09 00:03:00 CST 2015, time=2015-09-09, status=1, ipAttribution=)]

相关资讯

JCO:linifanib与索拉非尼对比用于晚期肝细胞癌

在《临床肿瘤学杂志》(JCO)上的一项III期临床试验中,Cainap等人发现,与索拉非尼(多吉美)治疗相比,linifanib治疗(一种VEGF和PDGF受体酪氨酸激酶ATP竞争抑制剂)并不能提高没有接受过系统治疗的晚期肝细胞癌患者的总生存期。研究细节在该项非盲试验中,研究对象主要是亚洲患者,1035例患者随机分为linifanib 17.5mg,1次/日(n=514)或索拉非尼400mg,2次

J Clin Gastroenterol:积极的治疗能延长原发性肝细胞癌患者的存活

目标和背景:巴塞罗那临床肝癌(BCLC)系统对肝细胞癌(HCC)体能状态(PS)3-4的患者建议最佳的支持治疗作为标准治疗。探讨治疗分配的理论基础。 研究:共2660例肝癌患者纳入进行回顾性分析。采用倾向评分匹配模型对体能状态 3和4之间的患者进行一对一配对接受支持治疗和抗肝癌治疗。存活分析采用 Kaplan-Meier 法和log-rank检验进行。Cox比例风险模型计算危害比。 结果:32

Oncotarget:PTPRO介导的自噬可以阻止脂肪肝和肝细胞癌发生

以往研究表明细胞自噬在非酒精性脂肪肝(NASH)和肝细胞癌(HCC)的进展中起非常重要的作用。蛋白酪氨酸磷酸酶受体O (PTPRO)是最近发现的肿瘤抑制因子,但是关于它在NASH的研究很少。近来有研究,证明PTPRO介导的细胞自噬与胰岛素抵抗、脂代谢、肝癌发生相关。 研究者选取同源的野生型小鼠(对照组)和ptpro−/−小鼠(试验组)作为实验对象,首先使用二乙基亚硝胺造NAS

Hepatology:瞬时弹性成像可预测亚临床肝硬化患者发生肝细胞癌的风险

为识别肝细胞癌(HCC)的高危人群,早期发现肝硬化患者的亚临床阶段是非常重要的。最近,来自韩国的一项研究评估了瞬时弹性成像技术(transient elastography TE)是否能够在无肝硬化临床表现的慢乙肝患者中识别出那些处于HCC高危的亚临床肝硬化(subclinical cirrhosis SCC)患者,研究成果发表在近期的Hepatology上。 方法 这是一项前瞻性研究,从20

动脉化疗栓塞和Y-90治疗肝细胞癌

肝细胞癌(hepatocellular carcinoma,HCC)是世界性医疗难题,是肝脏最常见的原发恶性肿瘤,位居癌症相关死亡原因第三位。包括美国在内的几个发达国家中,原发性肝癌的发生率正在升高,且这种趋势可能会持续几十年。由于就诊时分期较晚、并发症、可用的肝脏移植供体数量有限等多方面的原因,仅10%的肝细胞癌患者适于根治性治疗。 2002年,由于两项随机对照试验报道,经动脉化疗栓塞(t

J Cancer Res Clin:MCT4或为肝细胞癌新的治疗靶点

单羧酸转运蛋白4(MCT4)是癌细胞糖酵解代谢的一个关键部件,对癌细胞恶性生物学行为也同样重要。近日,广州中山大学附属肿瘤医院和山东大学附属省立医院的外科学者对MCT4在肝细胞癌(HCC)患者中的表达情况、预后价值及其在肝癌细胞增殖和转移中的作用进行了研究,探讨其与癌症发生分子机制的关系,相关研究成果在线发表于12月2日的Journal of Cancer Research and Clinica

Baidu
map
Baidu
map
Baidu
map